BioVie (NASDAQ:BIVI) Releases Quarterly Earnings Results

BioVie (NASDAQ:BIVI) posted its quarterly earnings results on Tuesday. The company reported ($0.46) EPS for the quarter, Zacks reports.

BioVie Trading Down 3.2 %

Shares of BIVI traded down $0.06 during mid-day trading on Tuesday, hitting $1.80. The company’s stock had a trading volume of 400,384 shares, compared to its average volume of 949,359. The firm has a 50-day simple moving average of $2.20 and a 200 day simple moving average of $2.29. The firm has a market capitalization of $31.99 million, a P/E ratio of -0.16 and a beta of 0.47. BioVie has a 1-year low of $1.04 and a 1-year high of $33.10.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.